Drug Interactions between elagolix / estradiol / norethindrone and sebetralstat
This report displays the potential drug interactions for the following 2 drugs:
- elagolix/estradiol/norethindrone
- sebetralstat
Interactions between your drugs
elagolix sebetralstat
Applies to: elagolix / estradiol / norethindrone and sebetralstat
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Coadministration with potent and moderate CYP450 3A4 inducers may significantly decrease the plasma concentrations of sebetralstat, which is a substrate of the isoenzyme. In clinical studies, concomitant administration with the potent CYP450 3A4 inducer phenytoin (100 mg three times daily for 15 days) decreased sebetralstat peak plasma concentration (Cmax) and systemic exposure (AUC) by 66% and 83%, respectively. In addition, coadministration with the moderate CYP450 3A4 inducer efavirenz (600 mg once daily for 14 days) decreased sebetralstat Cmax and AUC by 63% and 79%, respectively. Reduced therapeutic effectiveness may occur.
MANAGEMENT: Concomitant use of sebetralstat with potent and moderate CYP450 3A4 inducers should be avoided.
estradiol elagolix
Applies to: elagolix / estradiol / norethindrone and elagolix / estradiol / norethindrone
Estradiol and other estrogen-containing medications may reduce the effectiveness of elagolix in treating your condition. If you require contraception, it is recommended that you use a non-hormonal form of contraception during treatment with elagolix and for one week after its discontinuation. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
norethindrone elagolix
Applies to: elagolix / estradiol / norethindrone and elagolix / estradiol / norethindrone
Elagolix may reduce the blood levels and effects of norethindrone. If you are using low-dose oral contraceptives, you may have an increased risk of breakthrough bleeding and unintended pregnancy. You should discuss the use of alternative or additional methods of birth control with your healthcare provider. If you take hormone replacement for menopause, notify your doctor if your medication is no longer controlling your symptoms or you experience abnormal bleeding. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food/lifestyle interactions
sebetralstat food/lifestyle
Applies to: sebetralstat
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Coadministration with grapefruit juice may increase the plasma concentrations of sebetralstat. The mechanism is decreased clearance of sebetralstat due to inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits. The interaction has not been studied with grapefruit juice but has been reported for the potent CYP450 3A4 inhibitor, itraconazole. In a clinical study, sebetralstat peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 2.4-fold and 5.2-fold, respectively, following concomitant administration of the potent CYP450 3A4 inhibitor, itraconazole (200 mg once daily for 6 days). In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Increased exposure to sebetralstat may increase the risk and/or severity of adverse effects such as headache and QT prolongation. The use of sebetralstat alone at doses 2.5 times the maximum recommended dose has been associated with a mean increase in corrected QT (QTc) interval of 10.4 msec. Although clinical data are lacking for sebetralstat, in general, prolongation of the QT interval may increase the risk of ventricular arrhythmias such as ventricular tachycardia and torsade de pointes.
MANAGEMENT: Consumption of food or drinks containing grapefruit should generally be avoided during treatment with sebetralstat.
norethindrone food/lifestyle
Applies to: elagolix / estradiol / norethindrone
Grapefruit juice may increase the blood levels of certain medications such as norethindrone. You may want to limit your consumption of grapefruit and grapefruit juice during treatment with norethindrone. However, if you have been regularly consuming grapefruit or grapefruit juice with the medication, then it is advisable for you to talk with your doctor before changing the amounts of these products in your diet, as this may alter the effects of your medication. Contact your doctor if your condition changes or you experience increased side effects. Orange juice is not expected to interact.
estradiol food/lifestyle
Applies to: elagolix / estradiol / norethindrone
Information for this minor interaction is available on the professional version.
norethindrone food/lifestyle
Applies to: elagolix / estradiol / norethindrone
Information for this minor interaction is available on the professional version.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.